Abstract
The lack of new antibacterials for the treatment of serious infections has been broadly recognized as a major unmet medical need for at least a decade. A recent survey of 96 intensive care doctors across Europe showed that 50% have treated at least one patient with a gram-negative pathogen that was totally or almost totally resistant to all antibiotics during the previous six months. This is a dire predicament, as it is expected that no entirely novel mechanism agent for the treatment of gram-negative infections will be launched before 2015. Furthermore, recent experience with H1N1 pandemic influenza emphasizes the urgency of the situation, as bacterial coinfection with MRSA was implicated in a surprising proportion of fatalities. This phenomenon is especially worrying, since few oral treatment options exist for MRSA pneumonia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
